|
Ramucirumab for patients with intermediate-stage hepatocellular carcinoma (HCC) and elevated alpha fetoprotein (AFP): Pooled results from two phase III studies (REACH and REACH-2). |
|
|
Honoraria - Bayer; Bayer; Bayer; Bayer; Eisai; Eisai; Eisai; Eisai; MSD; MSD; MSD; MSD |
Consulting or Advisory Role - Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Eisai; Eisai; Eisai; Eisai; MSD; MSD; MSD; MSD; Ono Pharmaceutical; Ono Pharmaceutical; Ono Pharmaceutical; Ono Pharmaceutical |
Research Funding - Abbvie (Inst); Abbvie (Inst); Abbvie (Inst); Abbvie (Inst); EA Pharma (Inst); EA Pharma (Inst); EA Pharma (Inst); EA Pharma (Inst); Eisai (Inst); Eisai (Inst); Eisai (Inst); Eisai (Inst); Gilead Sciences (Inst); Gilead Sciences (Inst); Gilead Sciences (Inst); Gilead Sciences (Inst); Otsuka (Inst); Otsuka (Inst); Otsuka (Inst); Otsuka (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Takeda (Inst); Takeda (Inst); Takeda (Inst) |
|
|
Consulting or Advisory Role - AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Bayer; Bayer; Bayer; Bayer; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Eisai; Eisai; Eisai; Eisai; Exelixis; Exelixis; Exelixis; Exelixis; Genentech/Roche; Genentech/Roche; Genentech/Roche; Genentech/Roche; Lilly; Lilly; Lilly; Lilly; Merck; Merck; Merck; Merck; Novartis; Novartis; Novartis; Novartis; Pfizer; Pfizer; Pfizer; Pfizer |
Research Funding - Bayer (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Eisai (Inst); Eisai (Inst); Eisai (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Pfizer (Inst); Pfizer (Inst); Pfizer (Inst); Pfizer (Inst); Roche/Genentech (Inst); Roche/Genentech (Inst); Roche/Genentech (Inst); Roche/Genentech (Inst) |
Expert Testimony - Novartis; Novartis; Novartis; Novartis |
|
|
Honoraria - AstraZeneca; AstraZeneca; Bayer; Bayer; Eisai; Eisai; Lilly; Lilly |
Research Funding - AstraZeneca; AstraZeneca; Bayer; Bayer; Eisai; Eisai; Lilly; Lilly; MSD; MSD; Shionogi; Shionogi |
|
|
No Relationships to Disclose |
|
|
Honoraria - Bayer Yakuhin; Bayer Yakuhin; Bayer Yakuhin; Bayer Yakuhin; Bristol-Myers Squibb Japan; Bristol-Myers Squibb Japan; Bristol-Myers Squibb Japan; Bristol-Myers Squibb Japan; Dainippon Sumitomo Pharma; Dainippon Sumitomo Pharma; Dainippon Sumitomo Pharma; Dainippon Sumitomo Pharma; EA Pharma; EA Pharma; EA Pharma; EA Pharma; Eisai; Eisai; Eisai; Eisai; Gilead Sciences; Gilead Sciences; Gilead Sciences; Gilead Sciences; Kaken Pharmaceutical; Kaken Pharmaceutical; Kaken Pharmaceutical; Kaken Pharmaceutical; Lilly Japan; Lilly Japan; Lilly Japan; Lilly Japan; MSD; MSD; MSD; MSD; Mylan; Mylan; Mylan; Mylan; Novartis; Novartis; Novartis; Novartis; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Teijin Pharma; Teijin Pharma; Teijin Pharma; Teijin Pharma |
Consulting or Advisory Role - ASLAN Pharmaceuticals; ASLAN Pharmaceuticals; ASLAN Pharmaceuticals; ASLAN Pharmaceuticals; Astellas Pharma; Astellas Pharma; Astellas Pharma; Astellas Pharma; Bayer Yakuhin; Bayer Yakuhin; Bayer Yakuhin; Bayer Yakuhin; Chugai Pharma; Chugai Pharma; Chugai Pharma; Chugai Pharma; Daiichi Sankyo; Daiichi Sankyo; Daiichi Sankyo; Daiichi Sankyo; Eisai; Eisai; Eisai; Eisai; Lilly Japan; Lilly Japan; Lilly Japan; Lilly Japan; Micron; Micron; Micron; Micron; MSD; MSD; MSD; MSD; Novartis; Novartis; Novartis; Novartis; Shire; Shire; Shire; Shire; Teijin Pharma; Teijin Pharma; Teijin Pharma; Teijin Pharma |
Research Funding - ASLAN Pharmaceuticals (Inst); ASLAN Pharmaceuticals (Inst); ASLAN Pharmaceuticals (Inst); ASLAN Pharmaceuticals (Inst); AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Bayer Yakuhin (Inst); Bayer Yakuhin (Inst); Bayer Yakuhin (Inst); Bayer Yakuhin (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Chugai Pharma (Inst); Chugai Pharma (Inst); Chugai Pharma (Inst); Eisai (Inst); Eisai (Inst); Eisai (Inst); Eisai (Inst); J-Pharma (Inst); J-Pharma (Inst); J-Pharma (Inst); J-Pharma (Inst); Lilly Japan (Inst); Lilly Japan (Inst); Lilly Japan (Inst); Lilly Japan (Inst); Merck Serono (Inst); Merck Serono (Inst); Merck Serono (Inst); Merck Serono (Inst); MSD (Inst); MSD (Inst); MSD (Inst); MSD (Inst); NanoCarrier (Inst); NanoCarrier (Inst); NanoCarrier (Inst); NanoCarrier (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Ono Pharmaceutical (Inst); Ono Pharmaceutical (Inst); Ono Pharmaceutical (Inst); Takeda (Inst); Takeda (Inst); Takeda (Inst); Takeda (Inst); Yakult Pharmaceutical (Inst); Yakult Pharmaceutical (Inst); Yakult Pharmaceutical (Inst); Yakult Pharmaceutical (Inst) |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Bayer; Bayer; Bayer; Bayer; Blueprint Medicines; Blueprint Medicines; Blueprint Medicines; Blueprint Medicines; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Can-Fite BioPharma; Can-Fite BioPharma; Can-Fite BioPharma; Can-Fite BioPharma; Celsion; Celsion; Celsion; Celsion; Eisai; Eisai; Eisai; Eisai; Exelixis; Exelixis; Exelixis; Exelixis; Fortress Biotech; Fortress Biotech; Fortress Biotech; Fortress Biotech; Glycotest; Glycotest; Glycotest; Glycotest; Incyte; Incyte; Incyte; Incyte; Leerink; Leerink; Leerink; Leerink; Lilly; Lilly; Lilly; Lilly; Merck; Merck; Merck; Merck; Midatech Pharma; Midatech Pharma; Midatech Pharma; Midatech Pharma; Navigant Consulting; Navigant Consulting; Navigant Consulting; Navigant Consulting; Nucleix; Nucleix; Nucleix; Nucleix; Spring Bank; Spring Bank; Spring Bank; Spring Bank |
Research Funding - Bayer Schering Pharma (Inst); Bayer Schering Pharma (Inst); Bayer Schering Pharma (Inst); Bayer Schering Pharma (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Eisai (Inst); Eisai (Inst); Eisai (Inst); Ipsen (Inst); Ipsen (Inst); Ipsen (Inst); Ipsen (Inst) |
Travel, Accommodations, Expenses - Bayer; Bayer; Bayer; Bayer |
|
|
Honoraria - AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Bayer; Bayer; Bayer; Bayer; Eisai; Eisai; Eisai; Eisai; Ipsen; Ipsen; Ipsen; Ipsen; Lilly; Lilly; Lilly; Lilly; MSD; MSD; MSD; MSD |
Consulting or Advisory Role - Eisai; Eisai; Eisai; Eisai; Incyte; Incyte; Incyte; Incyte; Ipsen; Ipsen; Ipsen; Ipsen; MSD; MSD; MSD; MSD; Sanofi; Sanofi; Sanofi; Sanofi |
Travel, Accommodations, Expenses - Bayer; Bayer; Bayer; Bayer; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Sanofi; Sanofi; Sanofi; Sanofi |
|
|
Honoraria - AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Bayer; Bayer; Bayer; Bayer; Bristol-Myers Squibb/Medarex; Bristol-Myers Squibb/Medarex; Bristol-Myers Squibb/Medarex; Bristol-Myers Squibb/Medarex; Eisai; Eisai; Eisai; Eisai; MSD Oncology; MSD Oncology; MSD Oncology; MSD Oncology |
Consulting or Advisory Role - AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Bayer; Bayer; Bayer; Bayer; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Eisai; Eisai; Eisai; Eisai |
|
|
Employment - Lilly; Lilly; Lilly; Lilly |
Stock and Other Ownership Interests - Lilly; Lilly; Lilly; Lilly |
|
|
Employment - Lilly; Lilly; Lilly; Lilly |
Stock and Other Ownership Interests - Lilly; Lilly; Lilly; Lilly |
|
|
Employment - Lilly; Lilly; Lilly; Lilly |
Stock and Other Ownership Interests - Lilly; Lilly; Lilly; Lilly |
|
|
Employment - Lilly; Lilly; Lilly; Lilly |
Stock and Other Ownership Interests - Lilly; Lilly; Lilly; Lilly |
|
|
Employment - Lilly; Lilly; Lilly; Lilly |
Stock and Other Ownership Interests - Lilly; Lilly; Lilly; Lilly |
|
|
Employment - Lilly; Lilly; Lilly; Lilly |
Stock and Other Ownership Interests - Lilly; Lilly; Lilly; Lilly |
|
|
Consulting or Advisory Role - AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Bayer; Bayer; Bayer; Bayer; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Eisai; Eisai; Eisai; Eisai; Exelixis; Exelixis; Exelixis; Exelixis; Lilly; Lilly; Lilly; Lilly; Merck; Merck; Merck; Merck; Novartis; Novartis; Novartis; Novartis; Roche/Genentech; Roche/Genentech; Roche/Genentech; Roche/Genentech |
Research Funding - Bayer (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst) |